Results 21 to 30 of about 178 (95)

Levilimab in patients with COVID-19 in real-life practice [PDF]

Clinical pharmacology and therapy, 2021
To evaluate the efficacy and safety of levilimab in COVID-19 patients in the real-life clinical practice.
V.V. Mladov, P.S. Pukhtinskaia, D.N. Khobotnikov, E.A. Bezuglaya, M.A. Uyanaeva, G.Yu. Melik-Ogandzhanyan, G.G. Melkonyan, V.V. Strizheletskiy, T.A. Meleshkevich, S.R. Fridman, T.V. Bezuglaya, P.A. Plesovskiy, K.A. Lytkina, I.G. Ivanov, E.V. Tavlueva   +14 more
openaire   +1 more source

POS1214 THE DYNAMICS OF INFLAMMATORY MARKERS IN COVID-19 PATIENTS TREATED WITH LEVILIMAB [PDF]

Annals of the Rheumatic Diseases, 2021
Background: Levilimab (LVL) is a novel anti-IL6Rmonoclonal antibody against IL6Rα. Cytokine release syndrome plays the key role in the pathogenesis of a range of life-threatening conditions including the acute respiratory distress syndrome in severely ill COVID-19 patients.
N. Lomakin, B. Bakirov, G. Musaev, D. Protsenko, O. Moiseeva, E. Pasechnik, V. Popov, E. Smolyarchuk, I. Gordeev, M. Gilyarov, D. Fomina, V. Mazurov, M. Morozova, E. Dokukina, D. Bogdan, A. Lutskii, A. Zinkina-Orihan, I. Linkova, A. Seleznev   +18 more
openaire   +1 more source

Levilimab, a monoclonal antibody to IL-6 receptors, in COVID-19 [PDF]

Clinical pharmacology and therapy, 2021
Levilimab, a monoclonal antibody interacting with soluble and mebrane bound IL-6 receptors, was recently approved in Russia for the treatment of acute respiratory distress syndrome in COVID-19 patients. Efficacy and favorable safety profile of levilimab were shown in the randomised doubleblind placebo controlled CORONA trial in 206 patients with COVID ...
S. Moiseev, V. Nadtocheeva, L. Akulkina, V. Sholomova, M. Brovko, P. Novikov   +5 more
openaire   +1 more source

Efficacy and safety of levilimab, a monoclonal antibody to interleukin-6 receptors, in patients with rheumatoid arthritis [PDF]

Clinical pharmacology and therapy, 2021
Interleukin (IL)-6 is a proinlammatory cytokine contributing significantly to the pathogenesis of joint disease and systemic manifestations of rheumatoid arthritis (RA). Levilimab is a new original monoclonal antibody that blocks both soluble and membrane-bound IL-6 receptors.
S. Moiseev, E. Shchegoleva, P. Novikov
openaire   +1 more source

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions

MedComm, Volume 3, Issue 3, September 2022., 2022
The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis, with SARS‐CoV‐2 infection inducing excessive inflammation and cytokine storm. Cytokine storm leads to acute respiratory distress syndrome (ARDS) and multi‐organ failure, which are important causes of COVID‐19 progression and death.
Yujie Jiang, Tingmei Zhao, Xueyan Zhou, Yu Xiang, Pedro Gutierrez‐Castrellon, Xuelei Ma   +5 more
wiley   +1 more source

Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome

Mediators of Inflammation, Volume 2022, Issue 1, 2022., 2022
In recent decades, many serious respiratory infections have broken out all over the world, including SARS‐CoV, MERS, and COVID‐19. They are characterized by strong infectivity, rapid disease progression, high mortality, and poor prognosis. Excessive immune system activation results in cytokine hypersecretion, which is an important reason for the ...
Peixian Chen, Yan Tang, Weixin He, Ruixuan Yang, Zhien Lan, Ruirong Chen, Peidong Zhang, Shin-ichi Yokota   +7 more
wiley   +1 more source

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study

Научно-практическая ревматология, 2021
Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II study.Objective: to evaluate the efficacy safety and immunogenicity of LVL in methotrexate (MTX)
V. I. Mazurov, E. G. Zotkin, I. Z. Gaydukova, E. P. Ilivanova, T. V. Kropotina, T. V. Plaksina, O. B. Nesmeyanova, N. F. Soroka, E. A. Kunder, E. A. Dokukina, Yu. N. Linkova, N. A. Kravtsova, P. S. Pukhtinskaya, A. V. Eremeeva, A. V. Zinkina-Orikhan, A. A. Lutckii   +15 more
doaj   +1 more source

A Systematic Review with Meta-Analysis and Indirect Comparison of the Effectiveness of COVID-19 Anti-Interleukin Therapy

Антибиотики и Химиотерапия, 2023
Aim. Evaluation of the effectiveness of anti-interleukin drugs used in the pathogenetic therapy of COVID-19 in relation to the relative risks of 28-day mortality and the odds ratio of 14-day improvement of symptoms of the disease.
Yu. M. Gomon, A. S. Kolbin, A. M. Fahrutdinova, T. A. Usmanova, F. M. Sultanova, Yu. E. Balykina   +5 more
doaj   +1 more source

Clinical cases of complicated diverticulitis against the background of severe course COVID-19. Case report

Терапевтический архив, 2022
Two clinical cases of perforation of a previously undiagnosed colon diverticulum in patients with coronavirus infection caused by the SARS-CoV-2 virus treated at the Hospital №1 of Nalchik.
Natalia Yu. Pshenichcnaya, Zhanna B. Ponezheva, Asiyat R. Marzhokhova, Zaira F. Kharaeva, Liana E. Balagova, Madina Yu. Marzhokhova, Irina V. Shestakova   +6 more
doaj   +1 more source

Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis

Clinical pharmacology and therapy, 2022
Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR.
S. Moiseev, V. Logina, M. Litvinova, T. Shevtsova, N. Nosova, E. Kuznetsova, P. Novikov   +6 more
openaire   +1 more source